Search academic texts

Registration Number

0215U006061, 0111U010492 , R & D reports

Title

To define features of hormone and metabolic disturbances at patients with somatomammotropinoma and prolactinoma at hyper- and hypoprolactinaemia

popup.stage_title

Head

Khyzhnyak Oksana Olegovna,

Registration Date

30-01-2015

Organization

State Institution "V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine"

popup.description2

The object of study: patients with hormonally active pituitary tumors (somatomammotropinomas and prolactinomas). Objective: according to the nature of the clinical course somatomammotrophin and prolactin and on the basis of the identified features hormonal and metabolic disorders occurring against the background of hyper - and hypoprolactinemia, grounded approach to optimal suppressive therapy in patients with these endocrinopathies. Methods: clinical, biochemical, hormonal, immuno, tools, statistics. It was conducted a retrospective analysis (in the last 20 years), long-term results of treatment with somatomammotropin and prolactin according to the data of clinic of the Institute. It was studied the clinical course and the formation of complications in patients with somatomammotropinomas and prolactinomas depending on sex, age, character and severity, duration of disease and treatments applied. It was studied the peculiarities of disorders of protein, fat, carbohydrate and water-salt metabolism with prolonged hyperprolactinemia in patients with somatomammotropinomas and prolactinomas. It was clarified the character of disorders of protein, fat, carbohydrate and water-salt metabolism in patients somatomammotropinomas and prolactinomas pharmacologically induced on hypoprolactinemia caused by the appointment of suppressive therapy with dopamine agonists. It was identified the effect of pharmacologically induced hypoprolactinemia on the cardiovascular system and the pituitary-thyroid system. It was analyzed world experience on suppressive therapy with dopamine agonists in patients with somatomammotropinomas and prolactinomas and around the world. It was justified the optimal duration of suppressive therapy with dopamine agonists necessary to prevent recurrence of the disease. Scope: health, endocrinology, neurosurgery, internal medicine.

Product Description

popup.authors

Алексеєва Ірина Ігорівна
Барабаш Надія Евгенівна
Бастригіна Алла Олександрівна
Гогітідзе Теона Гурамівна
Завадська Наталія Володимирівна
Зайцева Людмила Іванівна
Курило Ольга Дмитрівна
Микитюк Мирослава Ростиславівна
Сидорова Ірина Василівна
Тихонова Тетяна Михайлівна
Тяжелова Ольга Володимирівна
Ушакова Лора Григорівна
Хижняк Оксана Олегівна

popup.nrat_date

2020-04-02